EDGE
Book a demo

Bio-printing

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Overview

Bioprinting is the process of using cells and biological material (called bioinks) for 3D printing structures that allow living cells to multiply and grow. The technology can be applied across multiple uses, including organ replacement, cosmetic surgery, and drug development. 

Advances in 3D printing technology have made bioprinting devices commercially viable. Bioprinting can be done using a range of methods, including magnetic levitation as well as inkjet-based, syringe-based, and laser-based printing. Going forward, its development will be focused on bioprinting devices and bioink materials, as having viable materials that can be safely implanted and used in the human body is key to the success of the industry. From a demand perspective, one of the primary drivers is the shrinking number of organ donors, along with population growth and the prevalence of chronic conditions that could be treated through organ and tissue replacement. 

*Note: Currently, we do not actively cover this industry, but we have identified it as a potential industry to add to our coverage.

More details

Market Mapping


Incumbents
Growth
Early
Seed
Pre-Seed
Bio-printer devices
?
Bio-printing services
?
Bio-inks
?
Bio-printing software
?
BioTherapeutics
BioTherapeutics
BioTherapeutics
BioTherapeutics
Rokit
Fluicell
nScrypt
EnvisionTEC
Arrayjet
Digilab
Formlabs
Nuclera
Cyfuse Biomedical
Inventia Life
3D Bioprinting Solutions
Axolotl Biosystems
Vivax Bio
Integrity Industrial Inkjet Integration
Poietis
Allegro 3D
Regemat 3D
Frontier Bio
UpNano
M3datek
Cellenion
3Dynamic Systems
Brinter
RegenHU
Printivo Group Jsc
FluidForm
Ouro_botics
Cellbricks
Auregen BioTherapeutics
GeSiM
Sygnis Bio Technologies
Cell Applications, Inc.
Modern Meadow
Prellis Biologics
Tissue Regeneration Systems
Medprin
Pandorum Technologies
Healshape
TeVido BioDevices
A.D.A.M.
Nano 3D Biosciences
Precise Bio
Sichuan Revotek
Advanced Biomatrix
InnoFluence
WeBio
VoxCell BioInnovation
ChemoSen3D
Theranosis Life Sciences
Next Big Innovation Labs
EDmicBio
Biolife4D
Collplant
Organovo
Allevi
Cellink
Dimension INX
Nanofiber Solutions
Volumetric
Blafar
Zetamatrix
PepPrint
Dipole Materials
Smart Tissues
TheWell Bioscience
Stratasys
Materialise NV
Aspect Biosystems
Advanced Solutions Life Sciences
Scispot
Bio3D Technologies
Morphodyne
Spheroid Revolution

The Disruptors


Bio-printer devices

?

Disruptors

?
Funding in USD Millions
Nuclera
69
Cyfuse Biomedical
30
Inventia Life
25
Frontier Bio
1
UpNano
Unknown
3D Bioprinting Solutions
Unknown
M3datek
Unknown
Cellenion
Unknown
Axolotl Biosystems
Unknown
3Dynamic Systems
Unknown
Vivax Bio
Unknown
Integrity Industrial Inkjet Integration
Unknown
Watchlist
?
Poietis
Brinter
Allegro 3D
Regemat 3D
RegenHU
Printivo Group Jsc
FluidForm
Ouro_botics
Cellbricks
Auregen BioTherapeutics
GeSiM
Sygnis Bio Technologies

Bio-printing services

?

Disruptors

?
Funding in USD Millions
Prellis Biologics
65
Tissue Regeneration Systems
18
Pandorum Technologies
14
A.D.A.M.
1
Precise Bio
Unknown
Sichuan Revotek
Unknown
Advanced Biomatrix
Unknown
Medprin
Unknown
InnoFluence
Unknown
WeBio
Unknown
Watchlist
?
Healshape
TeVido BioDevices
VoxCell BioInnovation
Nano 3D Biosciences
ChemoSen3D
Theranosis Life Sciences
Next Big Innovation Labs
EDmicBio
Biolife4D

Bio-inks

?

Disruptors

?
Funding in USD Millions
Organovo
112
Allevi
5
Cellink
4
Blafar
Unknown
Watchlist
?
Dimension INX
Nanofiber Solutions
Volumetric
Zetamatrix
PepPrint
Dipole Materials
Smart Tissues
TheWell Bioscience

Bio-printing software

?

Disruptors

?
Funding in USD Millions
Aspect Biosystems
24
Advanced Solutions Life Sciences
Unknown
Watchlist
?
Scispot
Bio3D Technologies
Morphodyne
Spheroid Revolution

Nuclera

Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins and genes.

Segment:
Bio-printer devices
Total funding:
USD 69.3 million
Disruptor Funding History

Bio-printer devices:

Nuclera
Cyfuse Biomedical
Inventia Life
Frontier Bio
Poietis
Brinter
Allegro 3D
Regemat 3D
RegenHU
Printivo Group Jsc
FluidForm

Bio-printing services:

Prellis Biologics
Tissue Regeneration Systems
Pandorum Technologies
A.D.A.M.
Healshape
TeVido BioDevices
VoxCell BioInnovation
Nano 3D Biosciences
ChemoSen3D
Theranosis Life Sciences

Bio-inks:

Organovo
Allevi
Cellink
Dimension INX
Nanofiber Solutions
Volumetric
Zetamatrix
PepPrint
Dipole Materials

Notable Investors


No investor data is available

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Book a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.